TTI-1612

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameTTI-1612

Drug Alias NameSoluble HB-EGF like growth factor - Stem Cell TherapeuticsSoluble heparin-binding epidermal growth factor-like growth factor - Stem Cell TherapeuticsTTI-1612

ClassificationBiologics

Mechanisms of ActionEpidermal growth factor receptor erbB1 agonistsEpithelial cells stimulantsIntracellular signaling peptides and proteins stimulants

TargetsIntracellular signaling peptides and proteinsEpidermal growth factor receptor erbB1

Therapy Area/IndicationsCystitis, Interstitial

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanada

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesTrillium Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesTrillium Therapeutics Inc

Active IndicationsN/A

Inactive IndicationsCystitis, Interstitial

Other Information

ATC CodeN/A